Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) EBITDA (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of EBITDA data on record, last reported at -$19.8 million in Q4 2025.

  • For Q4 2025, EBITDA rose 79.58% year-over-year to -$19.8 million; the TTM value through Dec 2025 reached -$64.4 million, up 51.15%, while the annual FY2025 figure was -$64.4 million, 51.15% up from the prior year.
  • EBITDA reached -$19.8 million in Q4 2025 per ACRS's latest filing, down from -$14.5 million in the prior quarter.
  • Across five years, EBITDA topped out at -$468000.0 in Q4 2023 and bottomed at -$96.9 million in Q4 2024.
  • Average EBITDA over 5 years is -$23.1 million, with a median of -$19.9 million recorded in 2022.
  • Peak YoY movement for EBITDA: skyrocketed 98.27% in 2023, then crashed 20601.28% in 2024.
  • A 5-year view of EBITDA shows it stood at -$23.0 million in 2021, then dropped by 17.55% to -$27.1 million in 2022, then surged by 98.27% to -$468000.0 in 2023, then plummeted by 20601.28% to -$96.9 million in 2024, then skyrocketed by 79.58% to -$19.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$19.8 million in Q4 2025, -$14.5 million in Q3 2025, and -$15.4 million in Q2 2025.